About: Progressive disease following autologous transplantation in patients with chemosensitive relapsed or primary refractory Hodgkin's disease or aggressive non-Hodgkin's lymphoma

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Progressive disease following autologous transplantation in patients with chemosensitive relapsed or primary refractory Hodgkin's disease or aggressive non-Hodgkin's lymphoma Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 01 October 2003

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) наукова стаття, опублікована в жовтні 2003 (uk) مقالة علمية تنشرت ف 1 أكتوبر 2003 (ary) im Oktober 2003 veröffentlichter wissenschaftlicher Artikel (de) artículu científicu espublizáu n'ochobre de 2003 (ast) scientific article published on 01 October 2003 (en)
publication date	wds:Q73401113-590EB26E-88F8-40E5-88AC-EC93E747520C
publication date	2003-10-01 00:00:00Z (xsd:dateTime)
exact match	wds:Q73401113-D7B554D1-2216-4C66-9545-60A5CD7B83B2
exact match	https://scigraph.springernature.com/pub.10.1038/sj.bmt.1704214
cites work	wds:Q73401113-0C66FEC4-81ED-40F7-812F-81E9FFDED5B1 wds:Q73401113-0D454BB8-20BA-4203-B598-176D65A4B6F6 wds:Q73401113-1677AAD6-D17E-463E-BD20-B0F17CC5D7B2 wds:Q73401113-1C655F04-4901-4F60-BC93-F28B901E2099 wds:Q73401113-2305A1E3-2295-45A8-B070-541B53802686 wds:Q73401113-295A88FF-6765-4349-816B-081310358EF2 wds:Q73401113-32A55C3E-641B-4A7C-9807-77700EFB6BB8 wds:Q73401113-36F2969A-3994-4FE4-87C4-17219E1DF519 wds:Q73401113-4247D605-ADDE-442D-A0C0-B986CC12FD74 wds:Q73401113-4457E52D-F6AE-4275-B5DC-5D4004C9992C wds:Q73401113-44799315-AFF1-4139-8328-622E474E4F79 wds:Q73401113-44B86DC2-BD34-4A6A-89DC-1C0722DF3B26 wds:Q73401113-49ED8F7C-9BB5-4E1B-ACE2-22BD45293D0D wds:Q73401113-4CFBE9A7-9427-4914-8473-00ED7D17EB81 wds:Q73401113-4D83F15D-FBF5-4FB8-9663-0D02D7F1DAB1 wds:Q73401113-5F49EA7B-DCA4-4BD9-8FE4-EA02850F7EDC wds:Q73401113-61CF7D0B-16DA-4008-A4E1-893EBCEAC68A wds:Q73401113-6596FDA2-76F7-4B3A-BE41-08E4582D9F34 wds:Q73401113-70E6292F-546E-4CDD-8F78-D2AC5C01DCF6 wds:Q73401113-7243EEE9-C9B9-4EE7-AF35-86A31656CC21 wds:Q73401113-7B32DE97-0C0D-4E06-B5A4-3E9D6E7A8E69 wds:Q73401113-8A108E65-7F81-4FE5-95C0-29091A1BB1B0 wds:Q73401113-91D8A041-972C-4DC2-A323-4BAB8CB62DD2 wds:Q73401113-9238F23D-AB8F-4C7A-8E33-442D8681313B wds:Q73401113-9629F24B-84E5-41F8-9900-F03F5F361199 wds:Q73401113-9778DBFB-A5C5-43AD-86EA-C9BC540A5362 wds:Q73401113-984D8FD0-4624-469B-9EB5-5C8C1400F127 wds:Q73401113-9A60D66D-F405-41F9-BD9C-D4567DB11514 wds:Q73401113-9E8FC898-FCF1-479A-B1FD-8167FD9DE9A2 wds:Q73401113-B361782D-9529-4676-9C85-3898734F8771 wds:Q73401113-BDB00981-3F33-4E27-9F46-8C79124B3DAC wds:Q73401113-E392B43B-6EC6-4014-96F9-F99E9C53CBCE
cites work	Rituximab: mechanism of action and resistance A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease Nonparametric Estimation from Incomplete Observations Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets Significance of molecular marker-positive cells after autologous peripheral-blood stem-cell transplantation for non-Hodgkin's lymphoma. High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. Bone marrow transplantation after failure of autologous transplant for non-Hodgkin's lymphoma A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial Autologous transplantation for diffuse aggressive non-Hodgkin's lymphoma in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry. The International Prognostic Factors Project score for advanced Hodgkin's disease is useful for predicting outcome of autologous hematopoietic stem cell transplantation Second allogeneic transplantation after failure of first autologous transplantation High-dose etoposide and melphalan, and autologous bone marrow transplantation for patients with advanced Hodgkin's disease: importance of disease status at transplant Second allogeneic stem cell transplantation using nonmyeloablative conditioning for patients who relapsed or developed secondary malignancies following autologous transplantation The role of intensive therapy and autologous blood and marrow transplantation for chemotherapy-sensitive relapsed and primary refractory non-Hodgkin's lymphoma: identification of major prognostic groups. The International Prognostic Index predicts for outcome following autologous stem cell transplantation in patients with relapsed and primary refractory intermediate-grade lymphoma. Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma High-dose BEAM chemotherapy with autologous peripheral blood progenitor-cell transplantation for unselected patients with primary refractory or relapsed Hodgkin's disease Successful allogeneic stem cell transplantation with nonmyeloablative conditioning in patients with relapsed hematologic malignancy following autologous stem cell transplantation. Rituximab for Aggressive Non-Hodgkin??s Lymphomas Relapsing After or Refractory to Autologous Stem Cell Transplantation Rituximab (anti-CD20 monoclonal antibody) therapy for progressive intermediate-grade non-Hodgkin's lymphoma after high-dose therapy and autologous peripheral stem cell transplantation Allogeneic bone marrow transplantation in patients who relapse after autologous transplantation. Patterns of relapse and subsequent management following high-dose chemotherapy with autologous haematopoietic support in relapsed or refractory Hodgkin's lymphoma: A two centre study Autotransplantation for relapsed or refractory Hodgkin's disease: long-term follow-up and analysis of prognostic factors Single-photon emission computed tomography gallium imaging versus computed tomography: predictive value in patients undergoing high-dose chemotherapy and autologous stem-cell transplantation for non-Hodgkin's lymphoma Progressive disease after ABMT for Hodgkin's disease Durability of remission after ABMT for NHL: the importance of the 2-year evaluation point
author name string	wds:Q73401113-1DCF80D6-B2CD-4D51-A44F-41EF5BC85D0E wds:Q73401113-40410AB4-C366-4B98-ACF1-CE3BD01FD462 wds:Q73401113-4F5E88EB-167A-4B7D-AB3C-4C21DD9B1B4D wds:Q73401113-6AFF127B-9BE4-435E-9852-C01A1E5EE8E7 wds:Q73401113-D436429D-EC9D-469A-BDF2-F54D436EC9B3 wds:Q73401113-DC0403DA-75A6-4D35-9C6B-97C0A2E85B7A
author name string	Qin J Moskowitz CH Nimer SD Yahalom J Kewalramani T Malhotra S
rdfs:label	Progressive disease following autologous transplantation in patients with chemosensitive relapsed or primary refractory Hodgkin's disease or aggressive non-Hodgkin's lymphoma (en) Progressive disease following autologous transplantation in patients with chemosensitive relapsed or primary refractory Hodgkin's disease or aggressive non-Hodgkin's lymphoma (nl)
skos:prefLabel	Progressive disease following autologous transplantation in patients with chemosensitive relapsed or primary refractory Hodgkin's disease or aggressive non-Hodgkin's lymphoma (en) Progressive disease following autologous transplantation in patients with chemosensitive relapsed or primary refractory Hodgkin's disease or aggressive non-Hodgkin's lymphoma (nl)
name	Progressive disease following autologous transplantation in patients with chemosensitive relapsed or primary refractory Hodgkin's disease or aggressive non-Hodgkin's lymphoma (en) Progressive disease following autologous transplantation in patients with chemosensitive relapsed or primary refractory Hodgkin's disease or aggressive non-Hodgkin's lymphoma (nl)
author	wds:Q73401113-17243949-27EA-4D29-97D0-CDE504911E65
author	Andrew D Zelenetz
title	wds:Q73401113-923CD1A8-E275-46D4-B106-42859BE2F485
title	Progressive disease following autologous transplantation in patients with chemosensitive relapsed or primary refractory Hodgkin's disease or aggressive non-Hodgkin's lymphoma (en)
page(s)	wds:Q73401113-FE01F94A-81BF-47B1-AF74-6FF7EA9D3216
page(s)	673-679
instance of	wds:Q73401113-C4DE4552-9ECC-4E2D-8D65-4409976209DF

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 172 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software